Treatment Guidelines for Acute Hepatic Porphyria and Primary Hyperoxaluria Type 1
These are two distinct genetic diseases requiring separate, disease-specific treatment protocols—there is no combined treatment guideline because they do not typically co-occur and have fundamentally different pathophysiologies.
Acute Hepatic Porphyria Management
Acute Attack Treatment
For acute attacks of hepatic porphyria, immediately discontinue all porphyrinogenic drugs, administer intravenous hemin, and provide supportive care with IV dextrose, opioid analgesia, and antiemetics 1.
The cornerstone approach includes:
- Immediate hemin administration: Intravenous hemin is the definitive treatment for moderate to severe acute attacks 1, 2
- IV dextrose: Administer oral or intravenous dextrose to suppress hepatic ALA synthase 1 1
- Remove precipitating factors: Stop all porphyrinogenic medications and chemicals immediately 1
- Symptom control: Use opioid analgesics for severe pain and antiemetics for nausea 1, 3
Diagnostic Confirmation During Acute Phase
Screen with random urine porphobilinogen (PBG) and δ-aminolevulinic acid (ALA) corrected to creatinine—do not delay treatment while awaiting results 1. All patients with elevated urinary PBG and/or ALA should be presumed to have AHP and treated accordingly 1. Genetic testing for pathogenic variants in HMBS, CPOX, PPOX, and ALAD genes confirms the specific AHP type after initial treatment 1.
Prophylactic Treatment for Recurrent Attacks
Patients with 4 or more acute attacks per year require prophylactic therapy with either subcutaneous givosiran or intravenous hemin 1, 2. Givosiran, an RNAi therapeutic targeting hepatic ALAS1 mRNA, has demonstrated superior efficacy in reducing recurrent attacks 2, 4. Alternative options for recurrent attacks include gonadotrophin-releasing hormone analogues for menstrual-related attacks 3.
Long-term Surveillance
Monitor for chronic complications including systemic arterial hypertension, chronic kidney disease, chronic liver disease, and hepatocellular carcinoma 1, 2. Liver transplantation is curative but reserved for patients with intractable symptoms who have failed all other treatment options 1.
Primary Hyperoxaluria Type 1 Management
Conservative Therapy (First-Line for All Patients)
Initiate conservative therapy immediately upon suspicion of PH1, including aggressive hyperhydration (3.5-4 L/day in adults; 2-3 L/m² BSA in children distributed throughout 24 hours) and potassium citrate (0.1-0.15 g/kg) in patients with preserved kidney function 5.
Additional conservative measures:
- Dietary modification: Balanced diet avoiding only extremely high oxalate foods 5
- Pyridoxine trial: Test responsiveness in all PH1 patients and titrate dose based on urinary oxalate excretion 5
- Monitor hydration: Use urinary markers with frequency dependent on disease severity 5
Advanced Kidney Disease Management
For PH1 patients with eGFR <30 ml/min/1.73m² who do not respond to pyridoxine and lack access to RNAi therapy, perform combined liver-kidney transplantation 5. The liver transplant must involve complete removal of the native liver 5.
For pyridoxine-responsive patients (homozygous for responsive mutations) with stage 5D CKD, isolated kidney transplantation is appropriate 5.
RNAi Therapy
Lumasiran is now available and targets glycolate oxidase mRNA, effectively reducing oxalate production and urinary excretion 6. This represents a major advance for patients who are not pyridoxine-responsive. Nedosiran, which blocks liver-specific lactate dehydrogenase A, is another emerging RNAi option 6.
Dialysis Management
When dialysis is required, use high-flux hemodialyzers (>1 m² capillary surface per 1 m² BSA) with maximal blood flow (>150-200 cm³/min/m² BSA) 5. Personalize the dialysis regimen to maintain plasma oxalate values in the range typical for kidney failure patients without PH 5.
Consider preemptive kidney replacement therapy before kidney failure develops in high-risk PH1 patients with elevated plasma oxalate or existing comorbidities 5.
Monitoring After Transplantation
Monitor urinary and plasma oxalate levels at least every 6 months after liver transplantation until normal values are achieved on three occasions 5. After kidney transplantation in patients receiving pyridoxine or RNAi therapy, monitor every 6 months until normalization, then annually 5.
Critical Distinction
These conditions require completely separate treatment algorithms. AHP involves acute neurovisceral crises requiring urgent hemin administration, while PH1 is a metabolic disorder causing progressive kidney damage from oxalate overproduction requiring aggressive hydration, citrate therapy, and potentially RNAi therapeutics or transplantation. Do not confuse the management of these two distinct genetic diseases.